Tech Company Financing Transactions
ReNAgade Therapeutics Funding Round
On 5/24/2023, ReNAgade Therapeutics announced $300 million in Series A investment from F2 Ventures and MPM Capital.
Transaction Overview
Company Name
Announced On
5/24/2023
Transaction Type
Venture Equity
Amount
$300,000,000
Round
Series A
Investors
F2 Ventures (Lead Investor)
MPM Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand operations, and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
640 Memorial Drive
Cambridge, MA 02139
US
Cambridge, MA 02139
US
Phone
Website
Email Address
Overview
The field of RNA medicine holds limitless, untapped potential to rewrite the underlying basis of disease. RNA medicines are currently limited by delivery to tissue targets and the absence of an integrated therapeutic platform. ReNAgade aims to overcome the limitations of RNA medicines by applying our comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amit Munshi
Chief Operating Officer
Ciaran Lawlor
Co-Founder
Ansbert Gadicke
Browse more venture capital transactions:
Prev: 5/24/2023: Ayar Labs venture capital transaction
Next: 5/25/2023: Checkmate venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs